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ABSTRACT 
Objectives: Omentin-1 is a novel adipokine that has a pivotal role in modulating the insulin 
sensitivity, immunity and inflammation. The current study was conducted to evaluate the se-
rum omentin-1 level in hepatitis C virus (HCV) infected patients, with or without type 2 dia-
betes, and to investigate its correlation with liver function parameters and insulin resistance.  
Methods: Eighty subjects were enrolled in this study divided into four groups: chronic HCV 
infected patients (n=20), chronic hepatitis C patients with concomitant type 2 diabetes (n=18), 
type 2 diabetic patients (n=22) and 20 healthy controls. Serum omentin-1 levels were assessed 
using enzyme-linked immunosorbent assay (ELISA). Fasting blood glucose, insulin levels, 
and liver parameters including aminotransferases (ALT and AST) were determined. 
Results: Serum omentin-1 levels were significantly elevated in HCV infected patients com-
pared to all other groups. Omentin-1 levels were positively correlated with AST and ALT 
levels (r =0.43, p< 0.001; r =0.423, p<0.001, respectively). Additionally, a significant nega-
tive correlation was found between omentin-1 and both fasting insulin levels and homeostasis 
model assessment of insulin resistance (HOMA-IR) (r = -0.238, p<0.05; r = -0.277, p<0.05, 
respectively). Furthermore, fasting blood glucose, HbA1c and HOMA-β were negatively cor-
related to serum omentin-1 levels however these correlations were not statistically significant. 
Conclusion: Serum omentin-1 level is elevated in HCV infected patients and is positively as-
sociated with liver enzymes AST and ALT. This suggested that omentin-1 may be implicated 
in the pathogenesis of hepatitis C and its metabolic complications. However its role needs to 
be elucidated by further studies. 
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INTRODUCTION 
Chronic hepatitis C (CHC) has been 
considered a metabolic disease rather than 
just a viral disease as it is usually associated 
with impaired glucose tolerance, insulin 
resistance, steatosis and changes in lipid 
metabolism (Mehta et al., 2000; Perlemuter 
et al., 2002). The prevalence of insulin re-
sistance (IR) and type 2 diabetes (T2D) has 
been demonstrated to be higher in chronic 
hepatitis C than non infected population 
(Torres and Harrison, 2008). This finding 
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was confirmed by studies shown that the IR 
in CHC patients is greatly improved after 
successful therapy of HCV (Simó et al., 
2006; Kawaguchi et al., 2007). Further-
more, it has been demonstrated that IR and 
T2D hasten the progression of liver fibrosis 
and cirrhosis in CHC patients (Hui et al., 
2003; Fartoux et al., 2005). Despite the 
close relationship between HCV infection 
and T2D, the underlying mechanisms that 
link both of them remain elusive.  
Adipokines are diverse group of media-
tors secreted from the adipose tissue. They 
have a potential role in modulating the insu-
lin sensitivity, immunity and inflammation 
(Rabe et al., 2008). Adipokines have been 
reported to play an important role in patho-
genesis of liver fibrosis and in the metabol-
ic consequences of liver disorders, however 
their role is not fully elucidated (Bertolani 
and Marra, 2008; Marra and Bertolani, 
2009; Yilmaz et al., 2011). A study by 
Kukla et al. (2010) has shown that serum 
adipokines (chemrin and leptin) were sig-
nificantly higher in patients with chronic 
hepatitis C compared to healthy controls. 
Additionally, chemrin was inversely corre-
lated with the inflammatory grade in CHC 
patients.  
Omentin-1 (Intelectin-1) is a newly 
identified protein that is highly and selec-
tively expressed in visceral adipose tissue 
(Schäffler et al., 2005). Omentin-1 may act 
as an endocrine factor affecting muscles, 
liver and omental adipose depot to enhance 
insulin sensitivity and glucose metabolism 
(Yang et al., 2006). Interestingly, circulat-
ing omentin-1 levels have been negatively 
correlated with obesity and insulin re-
sistance (Pan et al., 2010). Recently, a study 
by Yilmaz et al. (2011) has demonstrated 
that serum omentin-1 is elevated in patients 
with fatty liver diseases and it represents an 
independent predictor for hepatocyte bal-
looning in those patients. Another study by 
Eisinger et al. (2013) has reported that 
omentin-1 level is increased in liver cirrho-
sis but is not associated with complications 
of portal hypertension. However, the role of 
omentin-1 in the chronic hepatitis C and its 
metabolic consequences is unexplored yet. 
This led us to conduct the present study in 
which we investigated the levels of omen-
tin-1 in sera of chronic hepatitis C patients, 
with and without type 2 diabetes, and com-
pared them with its levels in healthy con-
trols.  Additionally, we evaluated the corre-
lation of omentin-1 with IR and biochemi-
cal parameters of liver injury.  
 
MATERIALS AND METHODS 
Study population 
Eighty subjects (65 male and 15 female) 
were enrolled in this study. They were clas-
sified into four groups: group 1 (HCV) 
comprised of patients with chronic HCV 
infection (n=20), group 2 (HCV/DM) pa-
tients suffering from both HCV and type 2 
diabetes (n=18), group 3 (DM) patients 
with type 2 diabetes (n=22), and group 4 
healthy controls (n=20).  Patients of groups 
2 and 3 were recruited from the National 
Institute of Diabetes and Endocrinology 
(NIDE). However, group 1 patients were 
recruited from the National Institute of En-
demic Diseases and Liver, El Kasr El-Einy, 
Cairo. 
Type 2 diabetes was diagnosed accord-
ing to WHO criteria (WHO, 2006). The du-
ration of diabetes was not more than 4 years 
in order to exclude any diabetic complica-
tions. On the other hand, chronic hepatitis C 
patients, with or without diabetes, showed 
abnormal serum aminotransferases for more 
than 6 months duration and showed positive 
results when tested for serum anti-HCV an-
tibodies. 
The following exclusion criteria were 
used for all subjects: hypertension, cardio-
pulmonary disease, renal disease, thyroid 
dysfunction, malignancy, smokers, alcohol-
ics, other causes of chronic liver disease as 
chronic hepatitis B, autoimmune hepatitis, 
acute hepatitis, haemochromatosis, hepato-
cellular carcinoma, biliary disorders.  Pa-
tients have previous interferon treatment or 
recently received any anti-inflammatory 
drugs were also excluded.  
The study was approved by the Re-
search Ethics Committee of the General 
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Organization for Teaching Hospitals and 
Institutes and the National Research Centre 
(Approval No. IDEG0147, Date 
25/6/2012). All subjects gave written in-
formed consent prior to participation in the 
study. The study was carried out in accord-
ance with the regulations and recommenda-
tions of the Declaration of Helsinki.  
A detailed patient’s history was ob-
tained; body mass index (BMI) was calcu-
lated as an index of the weight (in kilo-
grams) divided by the square of the height 
(in meters) measured on the same day of 
sample withdrawal.  
Overnight fasting blood samples were 
withdrawn from the antecubital vein. Blood 
samples were divided into three parts: the 
first part was collected into 0.5 M EDTA-
containing tubes for determination of gly-
cated heamoglobin (HbA1C), the second 
part was collected into fluoride-containing 
tubes for determination of FBG and the last 
part (6 ml) was collected into serum sepa-
rating tubes for determination of lipid pro-
file, liver function, serological testing (Anti 
HCV, HBsAG ), insulin and omentin-1  as-
say. Sera were separated by centrifugation 
at 3000 rpm for 10 min. Each serum sample 
was divided into several aliquots and kept 
at -80 °C until analysis.  
 
Laboratory assessments  
Serological testing: to exclude HBV in-
fection, hepatitis B surface antigen 
(HBsAg) was tested in serum by chromato-
graphic immunoassay using rapid test strip 
(Acon® Diagnostics, USA).  Anti-HCV 
antibodies were tested qualitatively by 
chromatographic immunoassay using rapid 
test strips provided by Acon® Diagnostics, 
USA. Serum aminotransferase (AST, ALT) 
were assayed colorimetrically according to 
Reitman and Frankel Method (Reitman and 
Frankel, 1957) using kits from Spectrum 
Diagnostics, Egypt. Fasting blood glucose 
was determined by colorimetric enzymatic 
hexokinase method (Siemens Healthcare 
Diagnostic, USA). Total cholesterol and 
triacylglycerol were determined by enzy-
matic colorimetric end point methods 
(Allain et al., 1974; Fossati and Prencipe, 
1982).  LDL cholesterol was determined 
according to heparin/citrate precipitation 
method and HDL cholesterol was measured 
according to phosphotungestic acid precipi-
tation method (Burstein et al., 1970; 
Castelli et al., 1977). All of lipid profile pa-
rameters were measured using kits provided 
by Spectrum Diagnostics, Egypt. HbA1C 
was determined using HPLC fully automat-
ed system with Bio-Rad D-10 Hemoglobin 
testing system (Jeppsson et al., 1986). All 
colorimetric and spectrophotometric assays 
were determined using appropriate semiau-
tomated photometer (JASCO®V-630UV-
Vis Spectrophotometer, USA).  
Serum insulin was estimated using insu-
lin enzyme-linked immunosorbant assay 
(ELISA) kit (DRG Insulin, DRG Interna-
tional Inc., USA) according to the manufac-
turer’s protocol.  Insulin resistance was de-
termined by the homeostasis model of as-
sessment (HOMA-IR) (Matthews et al., 
1985) using the formula: [fasting blood 
glucose (mg/dL) X fasting insulin 
(μIU/mL)]/405. Beta cell function was de-
termined by (HOMA-β) using the formula: 
[360×fasting insulin (μIU/mL)] / [fasting 
blood glucose (mg/dL) – 63] %. Serum 
omentin-1 concentrations were determined 
by enzyme-linked immunosorbant assay 
(ELISA) kit (CUSABIO Biotech Co., USA) 
according to the manufacturer’s instructions 
using ELx808™ Absorbance Microplate 
Reader, Bio-tek instruments, USA. 
 
Statistical analysis 
GraphPad Instat™ statistics software 
(1992-2000 Graph software Inc., V 3.05, 
Ralf Stahlman, Purdue Univ.931897 S) was 
used for data analysis. Results were ex-
pressed as mean ± SEM. To analyze more 
than two sets of data, ordinary one way 
analysis of variance (ANOVA) for paramet-
ric data was tried first, followed by Tukey-
Kramer multiple comparisons test, when 
Bartlett's test for homogeneity of variance 
was not-significant. If Bartlett's test was 
significant, logarithmic transformation of 
the individual data was performed before 
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testing ANOVA again, and then followed 
by Tukey-Kramer, when Bartlett's test be-
came not-significant. If logarithmic trans-
formation did not reduce variability be-
tween individual values shown as signifi-
cant difference of Bartlett's test, the com-
parison was carried out using ANOVA for 
non-parametric data (Kruskal Wallis test) 
followed by Dunn's test. The difference be-
tween groups was considered significant if 
the probability of error was ≤ 0.05. The cor-
relations between variables were deter-
mined by Pearson’s correlation coefficient. 
The analysis was repeated using multivari-
ate analysis of covariance (MANCOVA) 
which was adjusted for age using SPSS 
software program version 14 (SPSS Inc, 
Chicago, IL). 
  
RESULTS 
Table 1 displays the demographic data 
and the studied biochemical parameter for 
all groups. No significant difference was 
found among the studied groups in terms of 
BMI, triglycerides, total cholesterol, HDL 
cholesterol and LDL cholesterol.  However, 
diabetic and HCV/DM patients were char-
acterized by slightly higher mean age 
(48.9±1.553 and 45.83±1.952, respectively) 
compared to the healthy controls and HCV 
group (38.5±1.8 and 39.4±1.9, respective-
ly).  
Chronic hepatitis C patients, either dia-
betic or non-diabetic, had significantly 
higher AST and ALT levels compared to 
both control and diabetic groups as depicted 
in Table 1.  The fasting blood glucose lev-
els were increased significantly in diabetic 
group and HCV/DM group (166.18±17.9 
and 149.88±9.8, respectively) compared to 
control and HCV groups (92.1±2.8 and 
94.6±3.33, respectively). On the other hand, 
insulin levels in diabetic and HCV/DM pa-
tients were markedly higher than its levels 
in HCV patients and control subjects 
(11.3±1.5 and 9.18±1.19 vs. 7.08±0.6 and 
6.9±0.49). However, this increase was sta-
tistically significant only in the diabetic 
group (Table 1). 
 
 
Table 1: Demographic data and laboratory characteristics of the studied groups 
Parameters Control 
(n=20) 
HCV 
(n=20) 
HCV/DM 
(n=18) 
DM 
(n=22) 
p1 p2 p3 
Age (yrs) 38.5±1.8 39.4±1.9 45.8±1.9* 48.9±1.5*** <0.05 <0.01 NS 
Gender (M/F) 18/2 12/8 14/4 19/3 - - - 
BMI (Kg/m2) 23.6±0.4 23.8±0.4 23.9±0.4 24.3±0.3 NS NS NS 
FBS (mg/dl) 92.1±2.8 94.6±3.3 149.8±9.8** 166.2±17.9*** <0.01 <0.001 NS 
HbA1c (%) 6.09±0.2 5.5±0.1 6.5±0.463 7.4 ± 0.3* NS 0.001 NS 
AST (IU/L) 11.5±1.1 19.58±1.9* 23.26±3.1* 11.7±1.1 NS <0.05 <0.001
ALT(IU/L) 9.21±0.7 21.6±2.1*** 20.3±2.7*** 7.2 ± 0.7 NS <0.001 <0.001
TC (mg/dl) 142±4.4 142.3±5.8 142.7±8.7 148.6 ± 5.7 NS NS NS 
TAG(mg/dl) 123.6± 6.3 118.7± 12.5 123.4± 8.6 119.5±8.1 NS NS NS 
HDL.C (mg/dl) 50.2±2.3 45±2.5 46.7±3.98 42.1±1.9 NS NS NS 
LDL.C (mg/dl) 67±5.5 73.4±5.9 71.2±8.254 82.6±4.7 NS NS NS 
Insulin (μIU/mL) 6.9± 0.49 7.08± 0.6 9.18±1.19 11.3±1.5* NS <0.05 NS 
HOMA-IR 1.6±0.12 2.05±0.15 3.3±0.43* 4.3±0.59*** <0.05 <0.001 NS 
HOMA-β (%) 28.7±2.9 32.9±5.5 23.7±4.4 29.3±5.8 NS NS NS 
Omentin-1 
(ng/ml) 
11.1±1.5 29.5±6.64* 17.4±4.4 9.9±1.2 NS NS NS 
Data are represented as mean ± SEM. HCV: Hepatitis C virus infected patients; DM: patients with type 2 diabetes mellitus. * p 
<0.05, **p<0.01, ***p<0.001 compared to control group. p1- values for HCV and HCV/DM; p2- values for HCV and DM; p3- val-
ues for HCV/DM and DM. BMI: Body mass index; FBG: Fasting blood glucose; AST: Aspartate transaminase; ALT: Alanine 
transaminase; TC: total cholesterol; TAG: Triacylglycerol; HDL.C: high density lipoprotein cholesterol; LDL.C: Low density lipo-
protein cholesterol; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment 
of β cell function; NS: not significant. 
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Furthermore, diabetic and HCV/DM 
groups demonstrated significantly higher 
HOMA-IR values than the control group 
(p<0.001 and p<0.05, respectively) and 
HCV group (p <0.001, p < 0.05, respective-
ly). Yet, no significant difference was de-
tected among groups concerning the 
HOMA-β mean values.  
The levels of omentin-1 in all studied 
groups are depicted in Table 1. The HCV 
group demonstrated significantly higher 
omentin-1 values compared to the control 
group (p<0.05). Whereas, after omentin-1 
values were adjusted for age, HCV group 
showed significantly higher omentin-1 val-
ues than all other studied groups (Figure 1).  
Then we evaluated the correlation coef-
ficients of serum omentin-1 with all the 
studied parameters. Serum omentin-1 levels 
demonstrated significant positive correla-
tions with AST and ALT levels (r =0.4, p< 
0.001; r =0.423, p<0.001, respectively) 
(Figure 2). On the other hand, omentin-1 
levels revealed significant negative correla-
tion to fasting insulin levels and HOMA-IR 
(r = - 0.238, p<0.05; r = - 0.277, p<0.05, 
respectively). Furthermore, fasting blood 
glucose, HbA1c and HOMA-β were nega-
tively correlated to serum omentin-1 levels 
however those correlations did not reach 
statistical significance (Table 2). 
 
 
Figure 1: Age adjusted serum omentin-1 val-
ues in all studied groups. Data are expressed 
as mean ± SEM. 
 
 
Figure 2: Correlation of serum omentin-1 with 
ALT (A) and AST (B) 
 
 
Table 2: Correlations between omentin-1 levels 
and other studied parameters 
*Logarithmically transformed values with logarithmically 
transformed omentin values were used; p< 0.05 considered 
significant; NS: Non significant; FBG: fasting blood glucose; 
HbA1c: glycated hemoglobin; HOMA-IR: homeostasis mod-
el assessment of insulin resistance; HOMA-B: homeostasis 
model assessment of B-cell function. 
 
DISCUSSION 
Insulin resistance (IR) and type 2 diabe-
tes (T2D) have been demonstrated to be 
more prevalent among chronic hepatitis C 
than non infected population (Torres and 
Harrison, 2008). Despite the close relation-
ship between HCV infection and T2D, the 
underlying mechanisms of HCV-associated 
IR and diabetes remain elusive. Adipokines, 
chemrin and vaspin, have been reported to 
play a role in the pathogenesis of inflamma-
p r 2 r Parameter 
0.26490.017 -0.1304 FBG(NS) 
0.19950.02156 -0.146 HbA1c (NS) 
0.04010.05571 -0.238 Fasting  
insulin* 
0.01690.07673 -0.277 HOMA-IR* 
0.59680.00369 -0.0607 HOMA- B 
(NS) 
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tory process of CHC and IR caused by 
HCV (Kukla et al., 2010). However, this 
role is not fully understood.  
Omentin-1 (intelectin-1) is a newly 
identified adipokine that is highly and se-
lectively expressed in visceral adipose tis-
sue (Schäffler et al., 2005). Omentin-1 en-
hances insulin sensitivity and glucose me-
tabolism (Yang et al., 2006). Circulating 
omentin-1 level is elevated in non alcoholic 
fatty liver disease and is positively correlat-
ed with hepatocyte ballooning (Yilmaz et 
al., 2011). Yet, the role of omentin-1 in liv-
er disorders and their metabolic complica-
tions is still ambiguous. 
To our knowledge, the current study is 
the first study exploring the serum omentin-
1 levels in chronic hepatitis C patients with 
or without type 2 diabetes. A salient finding 
of our study is that serum omentin-1 levels 
were significantly elevated in HCV patients 
compared to healthy controls. So it seems 
that omentin-1 has a role in the pathogene-
sis of hepatitis. This finding is in agreement 
with a recent study by Eisinger et al. (2013) 
showing that omentin-1 is elevated in pa-
tients with liver cirrhosis.  Another study by 
Yilmaz and his coworkers (2011), has re-
ported that omentin-1 levels were signifi-
cantly higher in patients with non alcoholic 
fatty liver disease than in healthy controls. 
This finding may be explained, at least par-
tially, by the implication of omentin-1 in 
immune and inflammatory response. Ac-
cording to growing body of literature, 
omentin-1 (intelectin-1) is increased during 
bacterial infection (Tsuji et al., 2009), 
asthma (Kuperman et al., 2005), and meso-
thelioma (Wali et al., 2005). So it is thought 
that omentin-1 may play a pivotal role in 
innate immunity and inflammation. How-
ever its exact role is not fully elucidated.  
Furthermore, our results demonstrated 
that age adjusted omentin-1 levels in HCV 
/DM patients were significantly decreased 
compared to HCV patients. This may be 
explained by high glucose and insulin lev-
els in blood of HCV/DM patients compared 
to HCV patients without diabetes. It has 
been reported that plasma omentin-1 was 
declined after prolonged insulin-glucose 
infusion in healthy individuals. Additional-
ly, treating the human omental tissue ex-
plants with glucose and insulin caused 
down-regulation of omentin-1 expression 
(Tan et al., 2008a). Another study by 
Gürsoy et al. (2010) has reported that glu-
cose and insulin levels may have a repres-
sive effect on omentin-1 levels.  
In the last few years, several studies 
have reported that omentin-1 levels in type 
2 diabetic patients are decreased compared 
to healthy control (Tan et al., 2008b ; Pan et 
al., 2010; Gürsoy et al., 2010). In the cur-
rent study, the diabetic group of patients 
showed decreased omentin-1 level than 
healthy controls. Yet, this difference was 
not statistically significant. This finding is 
in accordance with a study by El-
Mesallamy et al. (2011) reporting that no 
significant difference was observed  in 
omentin-1 serum levels between the non-
obese group with type 2 diabetes, and the 
non-obese healthy control group (BMI 
< 30 kg⁄m2). Notably, all subjects enrolled 
in our study had normal BMI to avoid the 
variation in plasma omentin-1 level due to 
this factor which is one of the major deter-
minants of omentin-1 level as shown by 
several studies (De Souza Batista et al., 
2007; Gürsoy et al., 2010; El-Mesallamy et 
al., 2011).  
In accordance with previous studies, our 
results demonstrated that serum omentin-1 
level was negatively correlated with fasting 
insulin and HOMA-IR (De Souza Batista et 
al., 2007; Gürsoy et al., 2010; Yan et al., 
2011). Furthermore, in agreement to what 
was reported by De Souza Batista et al. 
(2007) the correlation of omentin-1 level 
with fasting blood glucose was not signifi-
cant in the present study. This finding is in 
opposition to others (Gürsoy et al., 2010; 
El-Mesallamy et al., 2011).  
On the other hand, omentin-1 level 
showed significant positive correlation with 
liver enzymes AST and ALT. This declares 
that, omentin-1 level is correlated to the 
hepatocyte degeneration. This finding is in 
agreement with a study by Yilmaz et al. 
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(2011) reporting that serum omentin-1 level 
is positively correlated with C reactive pro-
tein and hepatocyte ballooning suggesting 
an association between omentin-1 and 
hepatocyte death (Caldwell et al., 2010; 
Yilmaz et al., 2011). In aforementioned 
study, they did not correlate the serum 
omentin-1 level to AST and ALT levels. 
Additionally, it has been recently reported 
that omentin-1 induces the apoptosis of 
hepatocytes by increasing the stability of 
p53 (Zhang and Zhou, 2013). On the other 
hand, a recent study by Eisinger et al. 
(2013) has reported that omentin-1 is not 
associated with liver function in patients 
with liver cirrhosis. We have to point out 
that their study was conducted on liver cir-
rhosis caused by different etiologies which 
is different than the current study in which 
all patients were HCV infected patients.  
It is noteworthy that, information about 
serum omentin-1 levels in chronic hepatitis 
C patients are scanty and additional larger 
studies are required to confirm the findings 
of this study and to identify mechanisms for 
the paradoxical increase of omentin-1 levels 
in HCV patients. In conclusion, the salient 
finding of our study is the increased serum 
omentin-1 levels in HCV patients compared 
to the healthy subjects. Furthermore, serum 
omentin-1 showed significant positive cor-
relation with liver enzymes AST and ALT. 
Age adjusted omentin-1 values in HCV pa-
tients with type 2 diabetes were significant-
ly decreased compared to HCV patients not 
suffering from diabetes. This decline in 
omentin-1 levels may be attributed to in-
creased glucose and insulin levels in sera of 
diabetic patients which have suppressive 
effect of omentin-1 expression. This indi-
cates that omentin-1 may be implicated in 
the pathogenesis of hepatitis and its meta-
bolic complications however its role needs 
to be elucidated by future studies. 
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